FeesSafety
Pluang+

20/20 BioLabs Q3 2026 revenue rises 4.1%, expands cancer screening contracts and plans lab licensing in 2027

Company Fundamentals
16 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
20/20 BioLabs Q3 2026 revenue rises 4.1%, expands cancer screening contracts and plans lab licensing in 2027

20/20 BioLabs reported a 4.1% increase in OneTest™ revenue to $1.36 million for the first nine months of 2026, with gross margin improving to 32.8%. The company secured a two-year firefighter cancer screening contract in Vermont, expected to boost Q4 revenue, and continues testing in Maryland. It introduced a new laboratory franchise model and plans to license its tumor marker technology to labs in 2027 to expand distribution. With $3.63 million cash and no debt, 20/20 BioLabs aims for FDA authorization and Medicare reimbursement for OneTest™ by end of 2028.

20/20 BioLabs' recent financial results and business updates provide context for the health sector's market activity on Pluang. For readers following health-sector stocks, 31 out of 150 priced US stocks rose while 118 fell. Notable movers include ALMS at USD 5.04 with a 10.09% drop, RXRX at USD 2.90 with full buy activity, and NTRA at USD 291.45 with full buy activity. This data is as of Nov 17, 2026 03:31 WIB.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App